Targacept to Report Second Quarter Financial Results on August 5, 2009
Winston-Salem, North Carolina
July 29, 2009
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will report financial results for the second quarter ended June 30, 2009 on Wednesday, August 5, 2009, after the U.S. financial markets close.
Management will discuss the second quarter results, recent developments with regard to its product candidates TC-5214 and AZD3480, provide an update on the company's product development programs and business activities and discuss expectations for the future via conference call at 5:00 p.m. Eastern Daylight Time on August 5, 2009. The conference call may be accessed by dialing 866-730-5768 for domestic participants and 857-350-1592 for international callers (reference passcode 12179276). A replay of the conference call may be accessed beginning approximately two hours after the event and continuing through August 19, 2009 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 37510453).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Telephone: 336-480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Telephone: 508-362-3087
Email: linnmich@comcast.net
Back to Newsroom